"The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternat"...
Paresthesias (including burning, tingling, stinging) and/or pruritus, usually manifested in the perineal region are frequently experienced upon injection of the initial dose of LUSEDRA (fospropofol disodium injection) . Inform the patient that these sensations are typically mild to moderate in intensity, last a short time, and require no treatment.
Requirement for a patient escort should be considered. The decision as to when patients who have received LUSEDRA (fospropofol disodium injection) , particularly on an outpatient basis, may again engage in activities requiring complete mental alertness, coordination and/or physical dexterity (e.g., operate hazardous machinery, sign legal documents, or drive a motor vehicle) must be individualized.
Last reviewed on RxList: 2/10/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Lusedra Information
- Lusedra Drug Interactions Center: fospropofol iv
- Lusedra Side Effects Center
- Lusedra FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Chronic Pain/Back Pain
Find tips and advances in treatment.